登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>OX40 >CHEK-ATP053

HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line

For research use only.

  1. Genetically modified cell lines best reflect MOA (Mechanism of Action)
  2. Higher activity and larger assay window for robust and reproducible cell-based bioassay
  3. Comprehensive application data to support assay development and validation
  4. Full tracible record, stringent quality control and validated cell passage stability
  5. Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
  6. Global commercial license assistance whenever regulatory filing is required

描述(Description)

HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line

应用说明(Application)

Binding assay by FACS and cell based ELISA

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Puromycin (5 μg/mL)

培养基(Culture Medium)

DMEM medium + 10% FBS

冻存液(Freeze Medium)

10% DMSO + 90% FBS

装量(Quantity)

1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

Receptor Assay

OX40 FACS

FACS assay shows that Biotinylated Human OX40 Ligand, Avitag,Fc Tag (OXL-H82F4) can bind to HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line(HEK-ATP053). HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).

Protocol

如有相关细胞池需求请联系我们

 

背景(Background)

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

 

Limited Use&License Disclosure

  1. This cell line is provided for research use only. It is neither intended for any animal or human therapeutic use nor for any direct human in vivo use. You are restricted to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
  2. ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
  3. ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
  4. Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order.cn@acrobiosystems.com for further details.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
OX40靶点信息
英文全称:Tumor necrosis factor receptor superfamily member 4
中文全称:肿瘤坏死因子受体超家族成员4
种类:Homo sapiens
上市药物数量:0详情
临床药物数量:26详情
最高研发阶段:临床三期
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定